Survey of Chronic Myeloid Leukemia Patients Prescribed TKI(Descriptive study using DPC data)

Survey of Chronic Myeloid Leukemia Patients Prescribed TKI(Descriptive study using DPC data) - Survey of Chronic Myeloid Leukemia Patients Prescribed TKI(Descriptive study using DPC data)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055423

Enrollment

2000

Registered

2024-12-31

Start date

2023-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who were diagnosed with CML (ICD-10 code C92.1) during the enrollment period and started a prescription of TKI (Imatinib, Dasatinib, Nilotinib) (2) Patients who had tests for definitive diagnosis (hematologic tumor genetic testing, chromosomal testing) performed before the prescription of TKI (3) Patients who continued to be diagnosed with CML after the start of the TKI prescription

Exclusion criteria

Exclusion criteria: (1) Patients who were under 18 years of age at the time of the initiation of the TKI prescription (2) Patients who were prescribed TKI before the enrollment period

Design outcomes

Primary

Measure	Time frame
The prescribing patterns of TKI for each treatment line, the occurrence of cardiovascular events at the time of TKI prescription, the temporal transition of BCR-ABL1 (IS) at the time of TKI prescription, and the comorbidities at the time of TKI prescription.	—

Countries

Japan

Contacts

Public ContactYoshitsugu Kojima

Otsuka Pharmaceutical Co.,Ltd. Medical Affairs

kojimayo@otsuka.jp03-6717-1400

Outcome results